How RITUXAN Is Given

Depending on your regimen, treatment with RITUXAN is given in different ways. And RITUXAN has been shown to improve treatment results for many patients with NHL.

  • For initial treatment of follicular NHL with RITUXAN plus CVP chemotherapy, you may receive a RITUXAN infusion once every 3 weeks, for up to 8 infusions
  • After initial CVP chemotherapy for low-grade NHL, you may receive a RITUXAN infusion by itself, once weekly (for 1 month), followed by 5 months without treatment. This cycle may be repeated for up to 2 years (16 infusions)
  • After initial treatment of follicular NHL with RITUXAN plus chemotherapy, you may receive a RITUXAN infusion by itself once every 2 months for up to 2 years (12 infusions)
  • To treat low-grade or follicular NHL after the disease returns, you may receive a RITUXAN infusion by itself, once weekly, for up to 8 infusions
  • To treat DLBCL with RITUXAN plus CHOP chemotherapy, you may receive a RITUXAN infusion once every 3 weeks, for up to 8 infusions

Staying on your treatment

Treatment for cancer can be tough. To help you stay on treatment, it's important to find ways to help manage side effects. Ask your doctor for help. Remember, if your doctor recommends it, completing your therapy gives you the best chance to respond.

 
 

Need help paying for RITUXAN therapy?

Find out about Rituxan Access Solutions®.

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

Next Section For Family and Friends

Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

People with serious infections should not receive RITUXAN.

Important Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

CVP=cyclophosphamide, vincristine, and prednisone or prednisolone; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone.